Pimobendan increases survival of cardiomyopathic hamsters.
We investigated the effect of the new cardiotonic drug pimobendan on survival of hereditary cardiomyopathic hamsters. Untreated cardiomyopathic hamsters served as controls. A 50% mortality was observed after 280 days for the control group and after 318 days for the pimobendan-treated animals. After 340 days, survival was 0% for the untreated cardiomyopathic hamsters and 27% in the pimobendan-treated group. We conclude that pimobendan slows the progression of heart failure in cardiomyopathic hamsters.
van Meel
J C
JC
Division of Cardiovascular Pharmacology, Dr. Karl Thomae GmbH, Biberach/Riss, F.R.G.
Mauz
A B
AB
Wienen
W
W
Diederen
W
W
D000818:Animals; D009202:Cardiomyopathies / Q000188:drug therapy* / Q000401:mortality; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D006224:Cricetinae; D008297:Male; D011724:Pyridazines / Q000627:therapeutic use*
D002316:Cardiotonic Agents; D011724:Pyridazines; C041648:pimobendan